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IMMUNE RECONSTITUTION AFTER GENE THERAPY (GTX) FOR ADENO-
SINE DEAMINASE DEFICIENT SEVERE COMBINED IMMUNE DEFICIENCY
(ADA-SCID)
Sokolic, R.1, Podsakoff, G.2, Muul, L.1, Engel, B.2, Jagadeesh, J.1,
Garabedian, E.1, Kesserwan, C.1, Carbonaro, D.3, Choi, Y.C.3,
Shaw, K.3, Hershfield, M.4, Wayne, A.5, Kohn, D.3, Candotti, F.1 1Na-
tional Institutes of Health, Bethesda, MD; 2Children’s Hospital of Phila-
delphia, Philadelphia, PA; 3Childrens Hospital Los Angeles, Los Angeles,
CA; 4Duke University Medical Center, Durham, NC; 5National Insti-
tutes of Health, Bethesda, MD
We report on immune reconstitution in 3 patients (pts) who re-
ceived GT for ADA-SCID. After conditioning with 75 mg/m2
busulfan, pts received 2–5  106 autologous CD341 bone marrow
cells/kg that had been exposed to two retroviral vectors, MND-
ADA and GCsapM-ADA. Chemotherapy was well tolerated,
although in two pts, return of neutrophil counts was delayed.
Post-transplant, indices of immunity improved or normalized. At
18 months after treatment, pt 301N’s absolute lymphocyte counts
(ALC’s) have been up to 600/ml (n.v. 2300–5400/ml). T-cell stim-
ulation index (SI) to phytohemmaglutinin (PHA) and serum immu-
noglobulins and IgG subclass levels have normalized. In addition,
the pt responded normally to tetanus, diphtheria, polio and haemo-
philus vaccines. Recently, he promptly recovered from a gram-neg-
ative central venous catheter infection. Pt 303N is 15 months after
treatment and her ALC have been up to 250/ml. PHA-SI and se-
rum IgA levels have normalized, although the pt remains on IVIG.
Pt 304C has been followed for 9 months. IgA has normalized, but
other indices of immunity remain low. She resumed ADA enzyme
replacement therapy after an episode of pneumonia. Nevertheless,
her mononuclear cell ADA activity and percent corrected cells con-
tinue to increase. In all three pts, ADA activity has risen from less
than 2 units to more than 30 units (n.v. 58–128 units), and toxic
adenosine metabolites have fallen to levels comparable to those
seen in pts who have engrafted after allogeneic hematopoietic cell
transplant. Retroviral vector-marked cells in the peripheral blood
vary from 0.1% (301N) to 15% (303N) of the pts’ circulating
mononuclear cells. A fourth patient was treated on October 2,
2008, and is not yet evaluable. In summary, after treatment with
myelosuppressive chemotherapy and bone marrow GTx, all 3
evaluable pts have shown improvement in laboratory indices of
ADA activity and of immunity. Of the two pts who have been ob-
served for more than a year off of PEG-ADA, one has had no infec-
tions and the other has answered two immunologic challenges as
well as one would expect of a normal child. The results are in line
with those reported by researchers in Italy and UK and indicate
that gene therapy for ADA-SCID can lead to measurable improve-
ment of immune function. While the degree of reconstitution is
only partial when assessed in the laboratory, clinical responses to
immunologic challenges appear to be robust.
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AMBULATORY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR
SEVERE PRIMARY IMMUNODEFICIENCY (PID) IN CHILDREN
Tse, W.T., Guarino, J., Schneiderman, J., Duerst, R., Jacobsohn, D.,
Chaudhury, S., Kletzel, M. Children’s Memorial Hospital, Northwestern
University Feinberg School of Medicine, Chicago, IL
Ambulatory HSCT has many potential benefits, but it is un-
known if it will increase the risk of complications. We studied am-
bulatory HSCT in children with severe PID utilizing a reduced-
intensity conditioning (RIC) regimen. In 2000–2008, 26 children
with PID (SCID (n 5 13), Hyper-IgM (4), Wiskott-Aldrich (2),
XLPD (2), IPEX (2), Omenn (1), NEMO (1), Chediak-Higashi
(1); median age, 0.6 year (range 0.1–17.4)) underwent HSCT after
RIC (fludarabine 30mg/m2/day  6; single-daily dose IV busulfan
 2, with targeted exposure based on area-under-the-curve (AUC)
of a test dose; rabbit ATG 2mg/kg/day  4). Patients received
treatment and care primarily in an ambulatory setting. They
were admitted for in-patient care if they had specific medical or
psychosocial needs. Between transplant day -10 and 1100, the
median number per patient of scheduled clinic visits, acute care
clinic visits and ER visits was 21 (range 0–27), 1 (0–4) and
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FROM A SIN-
GLE 4/6 MATCHED UNIT IS AN EFFECTIVE THERAPY FOR CHILDREN
WITH MALIGNANT AND NON-MALIGNANT DIAGNOSES: GOOD SUR-
VIVAL, LOW GRAFT FAILURE AND GRAFT-VS-HOST DISEASE IN A SINGLE
CENTER ANALYSIS OF 314 PATIENTS
Prasad, V.K.1, Mendizabal, A.2, Gill, P.1, Parikh, S.H.1, Szabolcs, P.1,
Driscoll, T.A.1, Page, K.1, Wood, S.1, Semmel, D.1, Martin, P.L.1,
Carter, S.2, Kurtzberg, J.1 1Duke University Medical Center, Durham,
NC; 2The EMMES Corporation, Rockville, MD
Background: Despite millions in unrelated registries, many pa-
tients, in particular the minorities can not find a suitable donor. In
contrast, with an inventory of 250,000 almost every patient will
find a 4/6 cord blood unit (CBU). We summarize a large single
center experience utilizing unrelated 4/6 matched CBU in pediatric
patients.
Methods: 314 consecutive patients (median age 6.1 years; range
0.5–21.3 years) undergoing myeloablative transplantation at Duke
between 08/1993 and 11/2007 with a single 4/6 matched (low reso-
lution for HLA-A and –B and high resolution –DRB1) CBU were
studied (median follow-up 6.9 years; range 0.9–15.1 yrs). The pa-
tients (63% male; 27% non-Caucasian; 38% CMV seropositive)
had malignant (61%; n5 192; de novo and secondary leukemia, lym-
phoma, MDS, others) and non-malignant (39%; n5 122; metabolic,
immunodeficiency, marrow failure; and hemoglobinopathies) diag-
noses. In total, 51% were mismatched at one and 49% at two class
I HLA loci. The median pre-cryopreserved and reinfused total nu-
cleated cell (TNC) doses were 6.16  107/kg (range, 0.86–38.23)
and 4.80  107/kg (range, 0.54–27.40), respectively. Statistics
included Kaplan-Meier, log-rank, and Cox models.
Results: Cumulative incidence (CINC) of neutrophil engraft-
ment (median 26 days) at 42 days was 77.7%(95%CI, 73.0%-
82.4%) and of platelet engraftment 50K (median 160 days) at 180
days was 52.1%(95%CI, 46.6%-57.6%). Primary graft failure and
autologous recovery occurred in 21 (6.7%) and 10 (3.2%) patients,
respectively. The 100-day CINC of acuteGVHD grades III-IV
was 13.6%(95%CI, 9.7%-17.5%). CINC of chronicGVHD at 1
year was 13.7%(95%CI, 9.8%-17.6%). The probabilities of overall
survival (OS) at 1 year and 3 years were 54.8%(95%CI, 49.1%-
60.1%) and 46.6%(95%CI, 40.9%-52.0%), respectively.
Factors affecting OS in Mutlivariate Analysis
1 year OS Long-term OS
Hazard
Ratio p-value
Hazard
Ratio p-value
Favorable
Factors
TNC
cryopreserved
x 10e7/kg
\ 2.5 1.00 1.00 Cell Dose . 2.5
. 2.5 0.41 0.0003 0.45 0.0005
HLA B Mismatch
0 or 1 Mismatch 1.00 1.00 0 or 1 mismatch over
2 mismatch 2.16 0.05 2.02 0.04 2 HLA-B mismatch
Recipient Gender
Male 1.00 1.00
Female 1.47 0.03 1.39 0.04 Male Recipient
In multivariate model, 1-year and long-term OS were better in
boys, pre-cryo TNC.2.5  107/kg, and 0 or 1 compared to 2
HLA-B mismatches. The OS in minority and Caucasian patients
was similar. The probability of relapse of malignancy at 5 yrs was
10.1%(95%CI 5.8%-14.4%).
Conclusion: Transplantation using single 4/6 matched CBU is
effective and carries low probabilities of graft failure, acute GVHD
grades III-IV and chronic GVHD in pediatric patients. Outcomes
are similar to those reported with better matched UCB grafts. These
results support the use of 4/6 matching CBU for patients lacking
matched related and unrelated donors improving access for all pa-
tients including the minorities.
